Therapeutic experience with transdihydrolisuride in Huntington's disease.
Transdihydrolisuride is an ergot derivative with mixed agonist and antagonist effects on central dopamine receptors. We gave the drug orally (1 mg daily) to 10 patients with Huntington's disease. In seven patients, the chorea improved with no adverse effects during the study.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy*; D008090:Lisuride / Q000031:analogs & derivatives / Q000627:therapeutic use*; D008297:Male; D008606:Mental Processes / Q000187:drug effects; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy; D009483:Neuropsychological Tests; D011897:Random Allocation; D011954:Receptors, Dopamine / Q000187:drug effects; D013997:Time Factors
D004873:Ergolines; D011954:Receptors, Dopamine; C006208:dironyl; D008090:Lisuride